Marco Dioguardi Burgio1, Dario Picone2, Giuseppe Cabibbo3, Massimo Midiri2, Roberto Lagalla2, Giuseppe Brancatelli2. 1. Section of Radiological Sciences, Department of Biopathology and Medical Biotechnologies DiBiMed, University of Palermo, Palermo, Italy. marco_dioguardi@hotmail.it. 2. Section of Radiological Sciences, Department of Biopathology and Medical Biotechnologies DiBiMed, University of Palermo, Palermo, Italy. 3. Section of Gastroenterology, Biomedical Department of Internal Medicine and Specialties DiBiMIS, University of Palermo, Palermo, Italy.
Abstract
PURPOSE: The purpose of the study is to compare the MR-imaging features of hepatocellular carcinoma (HCC) capsule appearance on gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging, using imaging-based presumptive diagnosis of HCC as the reference standard. METHODS: Gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging of 51 patients with 71 HCCs were retrospectively reviewed. Three readers graded in consensus, using a five-point scale, the presence (score 4-5) of capsule appearance on images obtained during T1-weighted GRE portal venous phase (PVP), 3-min phase, and hepatobiliary phase (HBP). The Fisher's exact test and the t student unpaired test were performed. RESULTS: A hyperintense capsule appearance was present either on PVP or 3-min phase in 11/46 and in 24/25 HCCs imaged with gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging, respectively (24% vs. 96% p < 0.001). A hypointense capsule appearance was present on HBP in 8/46 and 0/22 HCCs evaluated with gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging, respectively (17% vs. 0% p = 0.046). A capsule appearance was detected either on PVP, 3-min phase, or HBP in 17/46 (37%) HCCs after gadoxetic acid injection and in 24/25 (96%) HCCs after gadobenate dimeglumine injection (p < 0.001). CONCLUSIONS: A capsule appearance was more frequently seen on gadobenate dimeglumine-enhanced MR imaging when compared to gadoxetic acid-enhanced MR imaging.
PURPOSE: The purpose of the study is to compare the MR-imaging features of hepatocellular carcinoma (HCC) capsule appearance on gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging, using imaging-based presumptive diagnosis of HCC as the reference standard. METHODS:Gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging of 51 patients with 71 HCCs were retrospectively reviewed. Three readers graded in consensus, using a five-point scale, the presence (score 4-5) of capsule appearance on images obtained during T1-weighted GRE portal venous phase (PVP), 3-min phase, and hepatobiliary phase (HBP). The Fisher's exact test and the t student unpaired test were performed. RESULTS: A hyperintense capsule appearance was present either on PVP or 3-min phase in 11/46 and in 24/25 HCCs imaged with gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging, respectively (24% vs. 96% p < 0.001). A hypointense capsule appearance was present on HBP in 8/46 and 0/22 HCCs evaluated with gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging, respectively (17% vs. 0% p = 0.046). A capsule appearance was detected either on PVP, 3-min phase, or HBP in 17/46 (37%) HCCs after gadoxetic acid injection and in 24/25 (96%) HCCs after gadobenate dimeglumine injection (p < 0.001). CONCLUSIONS: A capsule appearance was more frequently seen on gadobenate dimeglumine-enhanced MR imaging when compared to gadoxetic acid-enhanced MR imaging.
Authors: Bohyun Kim; Jei Hee Lee; Jai Keun Kim; Hye Jin Kim; Young Bae Kim; Dakeun Lee Journal: Medicine (Baltimore) Date: 2018-06 Impact factor: 1.889
Authors: Christoph J Zech; Ahmed Ba-Ssalamah; Thomas Berg; Hersh Chandarana; Gar-Yang Chau; Luigi Grazioli; Myeong-Jin Kim; Jeong Min Lee; Elmar M Merkle; Takamichi Murakami; Jens Ricke; Claude B Sirlin; Bin Song; Bachir Taouli; Kengo Yoshimitsu; Dow-Mu Koh Journal: Eur Radiol Date: 2019-08-05 Impact factor: 5.315